Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ProMIS Neurosciences Inc. - Common Shares (NQ:PMN)

16.59 +2.54 (+18.07%)
Streaming Delayed Price Updated: 11:15 AM EST, Feb 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ProMIS Neurosciences Inc. - Common Shares

< Previous 1 2 3 4 5 Next >
News headline image
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
Crude Oil Falls; Dick's Sporting Goods Earnings Miss Views ↗
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling over 100 points on Tuesday. The Dow traded down 0.39% to 34,330.87 while the NASDAQ rose 0.24% to 13,530.50. The... 
Via Benzinga
Topics Earnings Stocks
News headline image
Why ProMIS Neurosciences Shares Are Trading Higher By 33%; Here Are 20 Stocks Moving Premarket ↗
Gainers Axcella Health Inc. (NASDAQ: AXLA) shares gained 65% to $0.2887 in pre-market trading after gaining 12% on Monday. The company recently posted a narrower-than-expected quarterly loss. 
Via Benzinga
News headline image
Why Macy's Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares jumped 42.8% to $5.60 after the FDA lifted clinical hold on the company’s FTX-6058 for sickle cell disease. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
We're starting off Tuesday with a breakdown of the biggest pre-market stock movers investors will want to keep an eye on! 
Via InvestorPlace
News headline image
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket ↗
Gainers Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time to start off trading for Tuesday with a breakdown of the biggest pre-market stock movers worth watching this morning. 
Via InvestorPlace
News headline image
Crude Oil Falls; GreenPower Motor Company Shares Spike Higher ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 0.25% on Monday. The Dow traded up 0.25% to 34,596.04 while the NASDAQ rose 0.92% to 14,243.64. The S&P 500, also rose,... 
Via Benzinga
News headline image
Why ProMIS Neurosciences Stock Surged Today ↗
ProMIS Neurosciences Inc. (NASDAQ: PMN) shares skyrocketed Monday after the company presented preclinical data supporting the potential therapeutic advantage of its lead candidate for Alzheimer's... 
Via Benzinga
News headline image
Nasdaq Gains 100 Points; Guaranty Bancshares Posts Upbeat Results ↗
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Monday. The Dow traded up 0.19% to 34,574.01 while the NASDAQ rose 0.71% to 14,214.50. The S&P... 
Via Benzinga
News headline image
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived... 
Via Benzinga
News headline image
ProMIS Neurosciences (NASDAQ: PMN) Unveils Potential Therapeutic Advantage of PMN310 in Alzheimer’s Disease
Rationally Designed PMN310 Targets Toxic Amyloid-Beta Oligomers Selectively and Efficiently ProMIS Neurosciences, a pioneering biotech firm specializing in antibody therapeutics 
Via Spotlight Growth
News headline image
US Stocks Edge Higher; NY Empire State Manufacturing Index Falls In July ↗
U.S. stocks traded slightly higher this morning, with the Dow Jones moving higher by around 20 points on Monday. Following the market opening Monday, the Dow traded up 0.06% to 34,529.57 while the... 
Via Benzinga
News headline image
ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Announces Completion of Continuance
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
Why Icahn Enterprises Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Mobilicom Limited (NASDAQ: MOB) shares jumped 81.3% to $2.7187 after the company announced it received a commercial scale purchase order from Teledyne-FLIR for the production of drones for the... 
Via Benzinga
News headline image
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023
PMN310 demonstrated greater selectivity for target toxic oligomers over monomers compared to other amyloid-beta-directed antibodies. Greater selectivity of PMN310 for toxic oligomers indicates a... 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.